The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
Open accessAbstract
OBJECTIVE: To develop an evidence base for recommendations on the use of atypical antipsychotics for patients with schizophrenia. DESIGN: Systematic overview and meta-regression analyses of randomised controlled trials, as a basis for formal development of guidelines. SUBJECTS: 12 649 patients in 52 randomised trials comparing atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and sertindole) with conventional antipsychotics (usually haloperidol or chlorpromazine) or alternative atypical antipsychotics. MAIN OUTCOME MEASURES: Overall symptom scores. Rate of drop out (as a proxy for tolerability) and of side effects, notably extrapyramidal side effects. RESULTS: For both symptom reduction and drop out, there was substantial heterogeneity between the results of trials, including those evaluating the same atypical antipsychotic and comparator drugs. Meta-regression suggested that dose of conventional antipsychotic explained the heterogeneity. When the dose was </=12 mg/day of haloperidol (or equivalent), atypical antipsychotics had no benefits in terms of efficacy or overall tolerability, but they still caused fewer extrapyramidal side effects. CONCLUSIONS: There is no clear evidence that atypical antipsychotics are more effective or are better tolerated than conventional antipsychotics. Conventional antipsychotics should usually be used in the initial treatment of an episode of schizophrenia unless the patient has previously not responded to these drugs or has unacceptable extrapyramidal side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,348
A meta-analysis of randomized controlled trials: Efficacy of selenium treatment for sepsis
Li, S., Tang, T., Guo, P., Zou, Q., Ao, X., Hu, L., & Tan, L. (2019) · Medicine · doi:10.1097/md.0000000000014733 · Cited by 802
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Lehman, A. F., Steinwachs, D. M., & The Survey Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033303 · Cited by 598
Bayesian approaches to random-effects meta-analysis: a comparative study
Smith, T. C., Spiegelhalter, D. J., & Thomas, A. (1995) · Statistics in Medicine · doi:10.1002/sim.4780142408 · Cited by 568
Clozapine versus typical neuroleptic medication for schizophrenia
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059.pub2 · Cited by 329
Beasley, C. M., Dellva, M. A., Tamura, R. N., Morgenstern, H., Glazer, W. M., Ferguson, K., & Tollefson, G. D. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.1.23 · Cited by 241
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A., & Indran, S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001359.pub2 · Cited by 237
The positive and negative syndrome scale for schizophrenia
Obermeier, M. (2012) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.14936 · Cited by 225
Risperidone versus typical antipsychotic medication for schizophrenia
Hunter, R., Kennedy, E., Song, F., Gadon, L., & Irving, C. B. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000440 · Cited by 183
Clozapine versus typical neuroleptic medication for schizophrenia
Wahlbeck, K., Cheine, M. V., & Essali, A. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059 · Cited by 144
Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials
Bollini, P., Pampallona, S., Orza, M. J., Adams, M. E., & Chalmers, T. C. (1994) · Psychological Medicine · doi:10.1017/s003329170002729x · Cited by 129
Eccles, M., Freemantle, N., & Mason, J. M. (1998) · BMJ · doi:10.1136/bmj.316.7139.1232 · Cited by 127
Self-citationSrisurapanont, M., Maneeton, B., Maneeton, N., Lankappa, S. T., & Gandhi, R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000967.pub2 · Cited by 122
Health Services Research Methods
Shi, L. (1996) · Cited by 105
Kane, J. M., & McGlashan, T. H. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91630-x · Cited by 102
Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials
Song, F. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100116 · Cited by 78
Srisurapanont, M., Disayavanish, C., & Taimkaew, K. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000967 · Cited by 18
Olanzapine and tardive dyskinesia
Woods, S. W. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.175.4.391b · Cited by 16
Risperidone versus typical antipsychotic medication for schizophrenia
Carpenter, W. T. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0017-3 · Cited by 16
Cited by
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Self-citationSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Bayesian Approaches to Clinical Trials and Health‐Care Evaluation
Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2003) · Wiley eBooks · doi:10.1002/0470092602 · Cited by 1,673
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Self-citation
Metadata
- Authors
- Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2000-12-02
- Volume
- 321
- Issue
- 7273
- Pages
- 1371-1376
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2096635847
- Cited by
- 1,062
- References
- 26
- FWCI
- 45.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.